1 / 3

Analysis of CEA Levels and Median Overall Survival in Cancer Patients: Week 3-5 Results

This study presents the relationship between Carcinoembryonic Antigen (CEA) levels and median overall survival (OS) in cancer patients during weeks 3 to 5. Logrank tests indicated significant differences in OS based on CEA levels. For CEA < 0.25 ng/mL, the median OS was 24.9 months, while for CEA > 0.25 ng/mL, it was only 12.5 months, highlighting the prognostic value of CEA. Additionally, reductions in CEA levels showed a correlation with improved median OS, emphasizing the importance of monitoring CEA for treatment outcomes.

mahina
Télécharger la présentation

Analysis of CEA Levels and Median Overall Survival in Cancer Patients: Week 3-5 Results

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Figure S1 B A Logrank p<0.0001 Logrank p=0.0001 Week 3-5 Median OS CEA (ng/mL) N (%) Months (95% C.I.) CEA < 25 47 (41%) 24.9 (20.5 – NR) CEA > 25 68 (59%) 12.5 ( 9.4 – 16.2) Week 3-5 Median OS CEA (ng/mL) N (%) Months (95% C.I.) CEA < 50 63 (55%) 23.9 (16.8 – 29.3) CEA > 50 52 (45%) 12.5 ( 8.8 – 16.2) D C Logrank p<0.0062 Logrank p=0.1845 Week 3-5 CEA Median OS Reduction (%) N (%) Months (95% C.I.) >50% Reduction 42 (37%) 23.0 (13.6 – 29.3) <50% Reduction 73 (63%) 15.0 (11.1 – 18.8) Week 3-5 CEA Median OS Reduction (%) N (%) Months (95% C.I.) >25% Reduction 66 (57%) 23.0 (14.5 – 29.0) <25% Reduction 49 (43%) 12.6 ( 9.4 – 17.1)

  2. Figure S2 B A

  3. Figure S2 D C

More Related